N/A N=26 Probiotics for Chalaziosis Treatment in Children
Chalazion
Primary: Time Taken for a Complete Resolution of the Chalaziosis — 51.2; 28.4 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=594 Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in IOP in the Study Eye at Week 12 (Hours 0 and 2) — -6.46; -6.38; -6.05; -7.18 millimeters of mercury (mm Hg) — p=0.2950
Phase 1 N=76 A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Acute Myeloid Leukemia · Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With Treatment-Emergent Treatment Related Adverse Events Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory…
N/A N=297 The SAFE Study: Satisfaction and Adherence to Follow-Up With Colposcopy Exams
Uterine Cervical Dysplasia · Uterine Cervix Cancer
Primary: Anxiety — 37.3; 40.7 score on a scale
N/A N=53 Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation
Atrial Fibrillation · Inflammation
Primary: Atrial Fibrillation Burden — 2; 8.5 Percent time spent in atrial fibrillatio
Phase 2 N=30 The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study
Chronic Rhinitis
Primary: Change in Subjective Nasal Scoring — 0.62; 1.53 score on a scale — p=0.013
Phase 2 N=55 Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Lung Cancer
Primary: Dose-limiting Toxicity — 0 Dose-limiting toxicities
Phase 2 N=65 A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease
Crohn Disease
Primary: Number of Participants With Adverse Events — 2; 60; 60 Participants
Phase 4 N=853 Efficacy of Diosmectite (Smecta®) in the Symptomatic Treatment of Acute Diarrhoea in Adults
Acute Diarrhoea
Primary: Time to Recovery — 66.0; 68.6 Hours — p==0.2524
Phase 2 N=60 A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
Lymphoma
Primary: Objective Response Rate Based on Lugano Classification Criteria in Group A — 25.5 percentage
Phase 4 N=100 A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndromes
Primary: Proportion of Participants Achieving Erythroid Response at Week 12 as Assessed by International Working Group (IWG) 2006 Response Criteria — 60 Participants
Phase 2 N=7 Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB
Lower Urinary Tract Symptoms
Primary: Lactobacillus Safety — .286 Adverse Events — p==0.351
Phase 2 N=532 Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Irritable Bowel Syndrome With Constipation
Primary: Change From Baseline in Weekly Abdominal Pain Score Over the 12-Week Treatment Period: DR1 or IR vs. Placebo — -1.370; -1.938; -1.667; -1.656 score on a scale — p=0.0839
Phase 2 N=19 Blood Flow and Vascular Function in Cystic Fibrosis
Cystic Fibrosis
Primary: Acute Study: Percentage Flow-Mediated Dilation (FMD) — 7.8; 7.7; 7.3; 6.6 percent flow mediated dilation
N/A N=16 Assessing the Safety and Ability of SG1002 to Overcome Deficits in Hydrogen Sulfide in Heart Failure Patients
Heart Failure
Primary: Number of Subjects With Adverse Events — 2; 3; 2; 9 participants